Compare MMYT & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMYT | CDTX |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | India | United States |
| Employees | N/A | 73 |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.9B |
| IPO Year | 2010 | 2015 |
| Metric | MMYT | CDTX |
|---|---|---|
| Price | $85.99 | $220.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $120.00 | ★ $128.75 |
| AVG Volume (30 Days) | 980.0K | ★ 2.3M |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,011,011,000.00 | N/A |
| Revenue This Year | $19.90 | N/A |
| Revenue Next Year | $19.52 | N/A |
| P/E Ratio | $119.99 | ★ N/A |
| Revenue Growth | ★ 14.55 | N/A |
| 52 Week Low | $69.69 | $15.22 |
| 52 Week High | $122.35 | $221.20 |
| Indicator | MMYT | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.75 | 85.65 |
| Support Level | $69.69 | $219.79 |
| Resistance Level | $75.72 | $220.78 |
| Average True Range (ATR) | 2.94 | 0.69 |
| MACD | 2.03 | -4.30 |
| Stochastic Oscillator | 94.86 | 42.39 |
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.